Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

BACKGROUND: Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. Alemtuzumab is included as a recommended treatment for patients with highly active...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Bass, Ann D., Berkovich, Regina, Comi, Giancarlo, Eichau, Sara, Hobart, Jeremy, Hunter, Samuel F, LaGanke, Christopher, Limmroth, Volker, Pelletier, Daniel, Pozzilli, Carlo, Schippling, Sven, Sousa, Livia, Traboulsee, Anthony, Uitdehaag, Bernard M. J., Van Wijmeersch, Bart, Choudhry, Zia, Daizadeh, Nadia, Singer, Barry A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447657/
https://www.ncbi.nlm.nih.gov/pubmed/32710396
http://dx.doi.org/10.1007/s40263-020-00749-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447657/
https://www.ncbi.nlm.nih.gov/pubmed/32710396
http://dx.doi.org/10.1007/s40263-020-00749-x

Ejemplares similares